# The influence of human genetic variation on **Epstein-Barr virus sequence diversity**

Sina Rüeger<sup>1,2#</sup>, Christian Hammer<sup>3#</sup>, Alexis Loetscher<sup>2,4#</sup>, Paul J McLaren<sup>5,6</sup>, Dylan

Lawless<sup>1,2</sup>, Olivier Naret<sup>1,2</sup>, Daniel P. Depledge<sup>7</sup>, Sofia Morfopoulou<sup>7</sup>, Judith Breuer<sup>7</sup>, Evgeny 

Zdobnov<sup>2,4</sup>, Jacques Fellay<sup>1,2,8\*</sup> and the Swiss HIV Cohort Study 

- <sup>1</sup> School of Life Sciences, EPFL, Lausanne, Switzerland
- <sup>2</sup> Swiss Institute of Bioinformatics, Switzerland
- <sup>3</sup>Genentech Inc, 1 DNA Way, South San Francisco, CA, USA
- <sup>4</sup> Department of Genetic Medicine and Development, University of Geneva Medical School,
- Geneva, Switzerland
- <sup>5</sup> JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg,
- MB, Canada
- <sup>6</sup> Department of Medical Microbiology and Infectious Diseases, University of Manitoba,
- Winnipeg, MB, Canada
- <sup>7</sup> Division of Infection and Immunity, University College London, London, UK
- <sup>8</sup> Precision Medicine Unit, Lausanne University Hospital and University of Lausanne,
- Switzerland
- <sup>#</sup> These authors contributed equally to this work.
- \* Correspondence to jacques.fellay@epfl.ch.

20		
24		

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# Abstract 1

2 Epstein-Barr virus (EBV) is one of the most common viruses latently infecting 3 humans. Little is known about the impact of human genetic variation on the large inter-individual differences observed in response to EBV infection. To 4 5 search for a potential imprint of host genomic variation on the EBV sequence, we jointly analyzed paired viral and human genomic data from 268 HIV-6 7 coinfected individuals with CD4+ T cell count <200/mm<sup>3</sup> and elevated EBV 8 viremia. We hypothesized that the reactivated virus circulating in these patients could carry sequence variants acquired during primary EBV infection, thereby 9 providing a snapshot of early adaptation to the pressure exerted on EBV by the 10 individual immune response. We searched for associations between host and 11 12 pathogen genetic variants, taking into account human and EBV population 13 structure. Our analyses revealed significant associations between human and EBV sequence variation. Three polymorphic regions in the human genome were 14 found to be associated with EBV variation: one at the amino acid level 15 16 (BRLF1:p.Lys316Glu); and two at the gene level (burden testing of rare variants in BALF5 and BBRF1). Our findings confirm that jointly analyzing host and 17 18 pathogen genomes can identify sites of genomic interactions, which could help dissect pathogenic mechanisms and suggest new therapeutic avenues. 19

medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# 1 Introduction

Human genetic variation plays a key role in determining individual responses after exposure infectious agents. Even though susceptibility or resistance to a microbial challenge is the final result of dynamic interactions between host, pathogen, and environment, human genetic polymorphisms have been shown to have an important, directly quantifiable impact on the outcome of various infections [1,2].

7 Genome-wide association studies (GWAS) have proven powerful to identify genetic regions 8 implicated in a wide range of complex traits in both health and disease [3]. In the field of 9 infectious diseases, several clinical and laboratory phenotypes have been investigated, 10 including, for example disease susceptibility [4,5], clinical outcomes [6], adaptive immunity 11 [7,8,9] or drug response [10]. In chronically infected patients, however, the pathogen genome 12 itself provides a promising complementary target to investigate the impact of host genomic 13 diversity on infection. While one part of the variation observed in pathogen DNA or RNA 14 sequence is present at the transmission event, another fraction is acquired during the course 15 of an infection, resulting at least partially from selective pressure exerted by the host response 16 on the infectious agent. The phenomenon of within-host evolution has been extensively 17 investigated for both viruses [11,12,13] and bacteria [14,11]. Pathogen genomic variation can 18 thus be considered an intermediate phenotype that is detectable as a footprint of within-host 19 evolution. This can serve as a basis for a joint association analyses of host and pathogen 20 genome variation, which we called genome-to-genome (G2G) analysis [15], a more powerful 21 approach than using a clinical outcome alone. A global description of the adaptive forces 22 acting on a pathogen genome during natural infection holds the potential to identify novel 23 therapeutic and diagnostic targets and could inform vaccine design efforts [16].

24 A G2G analysis for the quickly evolving human immunodeficiency virus (HIV) identified strong 25 associations of single nucleotide polymorphisms (SNPs) in the HLA class I region with multiple amino acid variants across the viral genome [15]. More recent work showed an impact of 26 27 variation in the HLA class II and interferon lambda 4 (IFNL4) loci on hepatitis C virus (HCV) 28 sequence diversity [17,18,19]. While the rate of evolutionary change in RNA viruses is higher 29 than in DNA viruses [20], the latter also present considerable amounts of inter- and intra-host 30 variation. Among herpesviruses, it has been shown that human cytomegalovirus (HCMV) has 31 higher genomic variability than other DNA viruses [21]. Recent genome sequencing efforts 32 demonstrated that the same holds true for Epstein-Barr virus (EBV) [22,23].

33 EBV is a widespread human pathogen that causes infectious mononucleosis in about 10% of 34 individuals during primary infection. EBV infection occurs most often early in life, with about 35 30% of children being seropositive by age 5, 50% by age 10 and up to 80% by age 18 [24]. This human infecting herpesvirus has also been associated with post-transplant 36 37 lymphoproliferative disease [25] and could play a role in some autoimmune diseases [26,27]. 38 In addition, EBV has oncogenic properties and is implicated in the pathogenesis of multiple 39 cancer types, predominantly Burkitt's lymphoma, Hodgkin's and non-Hodgkin's lymphoma, 40 nasopharyngeal carcinoma and gastric carcinoma [28,29]. More than 5% of the 2 million 41 infection-associated new cancer cases in 2008 could be attributed to EBV [30]; it was also 42 estimated to have caused 1.8% of cancer deaths in 2010, i.e. more than 140,000 cases [31].

43 The EBV genome is approximately 170 Kbp long and encodes at least 80 proteins, not all of 44 which have been definitively identified or characterized. After primary infection, the EBV 45 genome persists in B cells as multicopy episomes that replicate once per cell cycle. In this

- 1 latent mode, only a small subset of viral genes is expressed. Latent EBV can then reactivate
- 2 to a lytic cycle, which involves higher gene expression and genome amplification for packaging
- 3 into new infectious viral particles [32].
- 4 A small number of host genomic analyses of EBV infection have been recently published.
- 5 demonstrating that human genetic diversity plays a role in disease outcome. A study in 270
- 6 EBV isolates from southern China identified two non-synonymous EBV variants within the
- 7 BALF2 gene that were strongly associated with the risk of nasopharyngeal carcinoma [33].
- 8 Another group investigated the co-evolution of worldwide EBV strains [34] and found extensive
- 9 linkage disequilibrium (LD) throughout EBV genomes. Furthermore, they observed that genes
- 10 in strong LD were enriched in immunogenic genes, suggesting adaptive immune selection and
- 11 epistasis. In a pediatric study of 58 Endemic Burkitt lymphoma cases and 40 healthy controls,
- 12 an EBV genome GWAS identified 6 associated variants in the genes EBNA1, EBNA2, BcLF1,
- 13 and BARF1 [35]. Finally, the narrow-sense heritability of the humoral immune response 14 against EBV was estimated to be 0.28 [9,36].
- 15 Here, we present the first global analysis of paired human and EBV genomes. We studied full
- 16 EBV genomes together with their respective host genomic variation in a cohort of 268
- 17 immunocompromised, HIV-coinfected patients. We chose untreated HIV-coinfected patients
- 18 because EBV reactivation leading to viremia is more prevalent in immunosuppressed
- 19 individuals than in an average population. Our analysis reveals three novel host genomic loci
- 20 that are associated with variation in EBV amino acids or genes.

# **Materials and Methods** 21

### 22 Study participants, sample preparation

23 The Swiss HIV Cohort Study (SHCS) is a nationwide, prospective cohort study of HIV-infected 24 patients that enrolled >20,000 individuals since its establishment in 1988 and prospectively 25 followed them at 6-month intervals [37]. For this project, SHCS participants were identified 26 based on written consent for human genetic testing and availability of a peripheral blood 27 mononuclear cell (PBMC) sample at time of advanced immunosuppression (i.e., with CD4+ T 28 cell count below 200/mm<sup>3</sup>) in the absence of antiretroviral treatment.

29 We obtained demographic and clinical information from the SHCS database. These included 30 sex, age, longitudinal HIV viral load results (number of RNA copies per ml of plasma), 31 longitudinal CD4+ T cell counts (number of cells per mm<sup>3</sup> of blood), and history of opportunistic

- 32 infections.
- 33 The SHCS has been approved by the Ethics Committees of all participating institutions
- 34 (Ethikkommission Nordwest- und Zentralschweiz, EKNZ; Kantonale Ethikkommission Bern;
- 35 Ethikkommission Ostschweiz, EKOS; Ethikkommission Zürich; Commission cantonale
- 36 d'éthique de la recherche sur l'être humain, Genève, CCER; Commission cantonale d'éthique
- 37 de la recherche sur l'être humain, Vaud, CER-VD; Comitato etico cantonale Ticino). Each 38 study participant provided written informed consent for genetic testing, and all research was
- 39 performed in accordance with relevant guidelines and regulations.

### EBV genome quantification, enrichment and sequencing 1

2 DNA was extracted from PBMCs using the MagNA Pure 96 DNA and the Viral NA Small 3 Volume Kit (Roche, Basel, Switzerland). Cellular EBV load was then determined using 4 quantitative real-time PCR. Samples that yielded > 100 viral copies / ul were selected for EBV 5 genome sequencing.

6 We used the previously described enrichment procedure to increase the relative abundance 7 of EBV compared to host DNA [38]. Shortly, baits covering the EBV type 1 and 2 reference 8 genomes were used to selectively capture viral DNA according to the SureSelect Illumina 9 paired-end sequencing library protocol. Samples were then multiplexed and sequenced on an

10 Illumina NextSeg sequencer [38].

### 11 **EBV** sequence analyses

12 We chose a reference-based approach to call variants in the pathogen data. Since EBNA-2

13 and EBNA-3s are highly variable between EBV-1 and EBV-2 strains, we suspected that reads 14 sequenced from these genes would map only to their corresponding type. In an attempt to

15 attenuate the reference-bias this could cause, we constructed two references, one with the

16 whole genome of the EBV-1 strain B95-8 (accession NC\_007605) and EBNA-2 and EBNA-3s

17 sequences from EBV-2 strain AG876 (accession NC 009334) and another one with the whole

18 genome of AG876 with the EBNA-2 and EBNA-3s sequences of B95-8.

19 The read libraries were processed through Trimmomatic [39] to remove remnant PCR tags.

20 TagDust [40] to eliminate low complexity reads and CD-HIT [41] to filter out duplicate reads.

21 The remaining sequence reads were aligned to the constructs described in the previous

22 paragraph. Following GATK best practices [42,43], we mapped the read libraries using BWA

23 mem [44]. We cleaned the regions around InDels using GATK v3.8's IndelRealigner [45]. As 24 a last pre-processing step, we applied bwa-postalt is, a BWA script that adjusts mapping

25 quality score in function of alignments on ALT haplotypes.

26 Because patients can be infected by multiple EBV strains [46], we used BWA's ALT-aware 27 ability. In short, reads mapping to an ALT contig were always marked as supplementary 28 alignment, regardless of mapping quality, unless they did not map to the primary assembly. 29 This makes it easy to find unambiguously mapped reads, which we used as markers to 30 guantify type 1 and type 2 EBV reads in all samples.

$$r1 = \frac{\# T1}{(\# T1 + \# T2) \cdot L1}$$
$$r2 = \frac{\# T2}{(\# T1 + \# T2) \cdot L2}$$

r = r1 - r231

32 where #T1 and #T2 are the unambiguous read counts against type 1 and 2 haplotypes,

33 respectively, L1 and L2 are the length of type 1 and 2 haplotypes, respectively, and r1 and r2 34 are the type 1 and 2 ratios, respectively. The score *r* is the relative abundance between type

35 1 and type 2. medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

## perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# 1 Definition of EBV amino acid variants

Since no gold standard variant set exists for EBV nor any closely related viral species, variant calling was performed using three different variant callers (GATK haplotypecaller, SNVer [47] and VarScan2 [48]) and by selecting as *bona fide* variant set the intersection of the three. The identified EBV variants were annotated using snpEff [49]. Nucleotide variants were transformed into binary amino acid matrices using in-house python scripts. The whole pipeline is written in Snakemake [50] and Python [51].

8 This approach was benchmarked using synthetic libraries generated from B95-8 and AG876 9 using ART Illumina and RNFtools, at a range of coverage between 10X and 250X and 5 10 different admixture conditions, 100% B95-8 or AG876, 75% - 25% and 50%-50%. Assessing 11 the true number of variants between EBV-1 and EBV-2 strains is not trivial because of the 12 high variability in EBNA-2 and EBNA-3s regions. Therefore, we rated the variant callers and 13 the consensus of the three mentioned callers on self-consistency. The performances of the 14 runs were measured using the ratio of the variant counts to the size of the union of all variants 15 called by a specific tested tool.

16 By using EBV type 2 as a reference, we focused on two types of variation in EBV strains: 1) 17 single amino acid variants; and 2) burden of very rare amino acid variants (present in only 1 18 sample) in each viral gene (Figure 1). We call these datasets EBV amino acids and EBV 19 genes, respectively. Both datasets contain binary values, with a value of 1 standing for "variant 20 present" and 0 for "no variant present". Positions with a coverage of less than 6x were set to 21 "missing" and samples with more than 80% missing positions were excluded entirely. The 22 positions covered by less than 6 reads were considered missing and imputed using the 23 imputePCA function implemented in the missMDA R-package [52]. In total, we obtained 4392 24 amino acid variants and 83 gene variants. However, to limit the risk of model overfitting and 25 because of low statistical power due to sample size we only included in the downstream 26 association analyses the 575 EBV amino acids with an amino acid frequency of more than 27 10% and 52 EBV genes.

28

29

medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . A. EBV genes and amino acids Example EBV genome BCRF1 **BNRF1** LMP1 83 genes in total Genes Modified from: https://wi.asm.org/content/93/2/e01593-18 Amino Glu > Ala Ser > Leu acids Reference G A G Т CG SNVs G C G B. Data Example BNRF1 gene C. Datasets ID SNV 1 SNV 2 SNV 3 SNV 4 SNV 5 SNV 6 🧃 575 EBV amino acids 1 = variant present 1 G G Т Т G A 0 = no variant present 2 G С G Т т G Vucleotides 3 G A G Т С G 52 EBV genes 4 G A G Т Т G Only aggregates amino acids that appear in one individual. 1 = at least one variant present 0 = no variant present Amino acid 1 Amino acid 2 ID

1 2

3 Figure 1: Illustration of EBV sequence variation.

Glu > Ala

0

1

0

0

1

2

З

4

acids

4mino ;

Ser > Leu

0

0

1

0

4 A) The EBV genome is about 170 Kbp long and contains 83 genes, for a total of 4392 amino 5 acid residues. As an example, we focus on the BNRF1 gene and on two amino acid changes: 6 Glu-Ala and Ser-Leu. We know for each sample the genomic variants across the whole

non-synonymous

amino acid variatior

7 genome, as illustrated with the colored nucleotides. Using the nucleotide information and a 8 reference genome we can compute the amino acid changes.

9 B) We compare each individual (ID) to reference data and encode an amino acid as 1 if that 10 individual has a non-synonymous change, and a 0 if not. This process returns us a matrix 11 containing binary values, with individuals as row, and amino acids as columns. In our example, 12 individual 2 has an amino acid change Glu-Ala and individual 3 an amino acid change

13 Ser→Leu.

14 C) To transform the data into outcomes for the G2G analysis we can use the amino acid matrix

15 as it is (EBV amino acids dataset) or remove all amino acid columns that appear in more than

16 1 individual and then pool amino acids per gene (1 = variant present, *EBV genes* dataset).

### Human genotyping and imputation 17

18 A subset of 84 participants had been genotyped in the context of previous studies on several

platforms. For the remaining 196 samples, human genomic DNA was isolated from PBMCs 19

20 with the QIAsymphony DSP DNA Kit (Qiagen, Hilden, Germany), and genotyped using

21 Illumina OmniExpress (v1.1) BeadChip arrays.

1 Genotype imputation was performed on the Sanger imputation server independently for all

2 genotyping platforms, using EAGLE2 [53] for pre-phasing and PBWT [54] with the 1000

3 Genomes Phase 3 reference panel [55]. Low-quality imputed variants were excluded based

4 on imputation INFO score (< 0.8). All datasets were merged, only keeping markers that were

- 5 genotyped or imputed for all genotyping platforms. SNPs were excluded on the basis of per-
- 6 individual missingness (> 3%), genotype missingness (> 1%), marked deviation from Hardy-7 Weinberg equilibrium ( $p < 1x10^{-6}$ ) and minor allele frequency < 5% (Table 1). All quality control
- 8 procedures were performed using PLINK 2.0 [56].

### 9 **Association analyses**

10 We used the mixed model association implementation for binary and continuous outcomes in 11 GCTA (v1.92) [57,58] to search for potential associations between human SNPs and EBV

12 variants. The model can be expressed with the following equation:

$$y_k = \alpha X + \beta^{(kl)} g_l + \eta + \varepsilon$$

14 where the outcome y is a binary vector indicating whether an EBV variant is present (1) or not 15 (0); X is a matrix that contains all covariates, a represents all fixed effects of all covariates 16 (including an intercept term), g is the SNP genotype vector with coded additive allele dosages 17 0, 1 or 2,  $\beta$  is the (fixed) effect of the SNP to be tested for association,  $\eta$  is the polygenic 18 (random) effect and  $\varepsilon$  the error term. This mixed model was estimated for each EBV variant 19 (k) and SNP (l), and integrated over all L SNPs and K EBV variants. To estimate n, the host 20 genetic relationship matrix (GRM) was calculated from QC preprocessed genotype data using 21 GCTA [57].

22 The use of a mixed effects association model allows to account for population stratification of 23 the host genome. To control for population stratification among EBV genomes, we included 24 the first six principal components (PCs) of EBV genetic variation to the covariate matrix X [59]. 25 Other covariates were sex, age and EBV type. PCs were calculated from EBV amino acid 26 variants using the convexLogisticPCA function from the R package logisticPCA [60] in R [61]. 27 As data preparation for PC computation, we removed variants with less than 5% or more than 28 95% frequency. Missing amino acid values were imputed with the imputePCA function from 29 the R package missMDA [52].

30 Significance was assessed using the usual genome-wide significance threshold in European populations of 5x10<sup>-8</sup> and dividing it by the effective number of GWASs performed [62]. We 31 32 used FINEMAP [63] to determine the most likely causal SNP(s) in a 2-Mb-wide window around 33 each significant SNP. FINEMAP requires GWAS summary statistics and LD estimations as 34 input. To estimate LD between SNPs, we used LDstore [64]. We performed eQTL lookups for 35 host SNPs in eQTLGen [65], EUGENE [66] and GTEx [67].

36 Unless otherwise specified, all data preparation and analyses were performed using R [61].

## **Code availability** 37

- 38 EBV data preparation: https://gitlab.com/ezlab/vir var calling
- 39 G2G Analysis: https://github.com/sinarueeger/G2G-EBV-manuscript

# **Results** 1

### Study participants and human genetic data 2

- 3 PBMC samples from 778 SHCS participants were screened for the presence of cellular EBV
- 4 DNA using RT-PCR. A total of 290 of them were identified as viremic for EBV (>2000 copies).
- 5 We obtained good quality human genotyping and EBV sequencing data for 268 of them, which
- 6 were included in the association analyses. The study cohort comprised 206 male and 62
- 7 female individuals, between the ages of 20 and 78 (median 40) (Table 1 and Supplementary
- 8 Figure S1).
- 9 We applied standard GWAS quality control (QC) procedures that yielded information for
- 10 4'291'179 SNPs (Table 1 and Supplementary Figure S2, which shows the distribution of the
- 11 minor allele frequency spectrum after QC).

## EBV genomic diversity and variant calling 12

13 Genome coverage was very uneven between the samples. Mean depth varied from less than

14 6x for 14 samples, up to more than 500x in 5 others. We also observed fluctuation in coverage

15 above 6x, which we used to exclude 12 samples in which less than 20% of the EBV genome

16 was sufficiently covered (Supplementary Figure S7a). In addition, the coverage in the first

17 sequencing batch was not uniform.

18 We estimated the clonality of EBV strain in each sample by taking advantage of the high 19 divergence between EBNAs T1 and T2 haplotypes. Among the 282 sequenced samples,

20 57.1% were predominantly (9:1) infected by T1 EBV, while 5.7% were mostly infected by T2

21 EBV (Supplementary Figure S6). The remaining 37.2% were infected by multiple strains or by

22 recombinant viruses. This approach does not allow to stratify further than the EBNA types.

23 The variant calling pipeline was adapted to output variants by minimizing the impact of the 24 admixture ratio and of the low coverage observed in the SHCS samples. Variants were called 25 against EBV-2, as EBV-2 was able to call more variants than EBV-1 (Supplementary Figure 26 S7d). The benchmark experiments against AG876 (EBV-2) yielded a total of 961 different 27 variants. The most conservative was SNVer (783 variants), while the most sensitive was 28 BCFtools (930 variants). The variant callers can be prone to artifacts [68], which was 29 specifically observed in SNVer (Supplementary Figure S7c) in these datasets. To reduce the 30 probability of calling artifacts, we chose to use the bona fide intersection of GATK HC, SNVer 31 and VarScan2. This approach is likely to be impacted by low coverage. The recall is stable at 32 around 95% at 25X coverage upwards and reasonable (10%) at 20X (Supplementary Figure 33 S7c). Hence, low coverage has an impact, specifically, half potential variants called, on only 34 15% of the SHCS sample. However, this approach is very conservative, since it outputs only 35 88%, 85% and 79% of the variants called by SNVer, GATK HC and VarScan2, respectively.

36 On average, around 800 amino acid variants were called for each sample, with slight 37 differences correlating with the clonality of the samples and the coverage above 6X 38 (Supplementary Figure S7d). The variant counts against the AG876 construct (EBV-2) were 39 generally higher in mixed infections and EBV-1 strains (Supplementary Figure S7d A). The 40 variant counts were generally lower in the samples included in the first sequencing batch, 41 which is likely due to the fluctuating coverage. However, overall, the number of variants was

1 found to be comparable across the samples, ranging from 400 to 1500 for the 77% samples

2 with a 6X coverage above 80% (Supplementary Figure S7d). Under 80% coverage, the variant

3 counts hardly exceed 500 but rarely drops under 200 either. It is therefore likely that we missed

- 4 variants using our approach. The positions covered by less than 6 reads were considered
- 5 missing and imputed afterwards using the imputePCA function implemented in the missMDA
- 6 R-package.
- 7 We analyzed EBV variation using two approaches: single marker analysis of EBV amino acids.
- 8 to investigate common viral variation, and burden testing of very rare amino acid variants in
- 9 EBV genes (Table 1, Supplementary Figure S3). Applying logistic principal component
- 10 analysis of viral genomic structure showed a single main cluster (Supplementary Figure S4).

### Genome-to-Genome association analysis 11

12 We tested for associations between each EBV variant and human SNPs. We studied 575 EBV

13 amino acids and 52 EBV genes, for a total of 627 GWASs. The effective number of GWASs

14 performed was 458. As covariates, we included the first six EBV principal components (51.4%

15 deviance explained), sex, age, type 1 vs 2 of EBV (Supplementary Figure S1). The sample 16

size ranged between 120 and 268, with a median sample size of 264. Sample size variation 17 was due to variable missingness in the EBV data. Genomic inflation factors for each of the

18 627 GWASs ranged between 0.92 and 1.12.

19 Significant associations ( $p < 1.09 \times 10^{-10}$ ) were identified between a total of 25 human SNPs 20 and viral variants mapping to three EBV regions (Table 2): the EBV genes BALF5 (Figure 2a) 21 and BBRF1 (Figure 2b) and the EBV amino acid BRLF1:p.Lys316Glu (Figure 2c). The minor 22 allele frequency of all significant host SNPs was between 0.05 and 0.10. The genomic inflation 23 factors of the three GWASs ranged between 0.95 and 0.96 (Q-Q plots shown in 24 Supplementary Figure S5).


- 25
- 26
- 27

28

- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38

10

medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .





8 Figure 2: Significant associations - A: BALF5, B: BBRF1, C: BRLF1:p.Lys316Glu.

9 The x-axis represents the chromosomal position and the y-axis displays the -log10(p-value). Colour alternates between chromosomes. Regions that contain statistically significant SNP 10


are presented in red (top SNP +/- 400 Kbp). The light grey dashed line represents the GWAS 11

12 significance threshold of 5x10<sup>-8</sup>, the dark grey dashed line the G2G threshold of 1.09x10<sup>-10</sup>.

- 1 Strong associations were observed between 17 SNPs in the UNC5D region on chromosome
- 2 8 and the occurrence of very rare functional variants in the EBV **BALF5** gene (Figures 2a, 3a),
- 3 which is involved in viral DNA replication during the late phase of lytic infection. UNC5D is a
- 4 poorly characterized gene expressed mainly in neuronal tissues, which encodes a protein that
- 5 has been shown to regulate p53-dependent apoptosis in neuroblastoma cells [69]. The top
- associated SNP, rs2950922 (OR = 1.31, 95%-CI = 1.21-1.41, P = 4.2x10<sup>-12</sup>, effect allele G), 6
- 7 is an eQTL for UNC5D in esophageal tissue (GTEx, [67]).
- 8 Rare amino acid variation in **BBRF1** was found to be associated with a single SNP,
- 9 rs62124869 (OR = 1.29, 95%-CI = 1.19-1.39, P = 4.2x10<sup>-11</sup>, effect allele C), which maps to the
- non-coding RNA gene LINC01830 (Long Intergenic Non-Protein Coding RNA 1830) on 10
- 11 chromosome 2 (Figures 2b, 3b).
- 12 Finally, 7 SNPs mapping to a non-coding region of chromosome 7 were found to be associated
- 13 with the EBV amino acid variant BRLF1:p.Lys316Glu (Figure 2c, 3c). The top SNP,
- rs6466720, had a p-value of 6.85x10<sup>-11</sup> and an OR of 1.41 (95%-CI = 1.28-1.58, effect allele 14
- 15 G). BRLF1 controls lytic reactivation of EBV from latency and regulates viral transcription.
- 16 BRLF1:p.Lys316Glu has not been described previously, but variation at the nearby residue
- 17 377 (BRLF1:p.Glu377Ala) has been shown to be prevalent in cases of nasopharyngeal and 18 gastric carcinomas in Chinese samples [70]. BRLF1:p.Lys316Glu and BRLF1:p.Glu377Ala
- 19 are in moderate LD (r2=0.55) in our dataset.
- 20

medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .



# 1 2

3 Figure 3: Locuszoom plots.

4 Locuszoom plots for the three EBV association signals highlighted in red in Figure 2 (A:

5 BALF5, B: BBRF1, C: BRLF1:p.Lys316Glu).

# **Discussion** 6

7 Because immunosuppression - and in particular T cell deficiency - favors EBV reactivation 8 from its latent B cell reservoir, EBV viremia is frequently detected in (untreated) HIV-infected 9 individuals with advanced disease and low CD4+ T cell counts. We hypothesized that the 10 reactivated virus circulating in these patients could carry sequence variants acquired during 11 primary EBV infection, thereby providing a snapshot of early adaptation to the pressure 12 exerted on EBV by the individual immune response.

13 To search for a potential imprint of host genomic variation on the viral sequence, we jointly 14 analyzed genomic information obtained from paired EBV and human samples. Viral sequence medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

variation can be seen as an intermediate phenotype, closer to potentially causal host polymorphisms than clinically observable outcomes like viral load or disease phenotypes. As such, it allows the detection of more subtle associations, less likely to be obscured by environmental influences. In our G2G analysis, we used variation at EBV amino acid residues as outcome in multiple parallel GWAS, which allowed us to obtain effect estimations between each human genetic variant and EBV variation.

We identified two EBV genes and one EBV amino acid as associated with three regions of the human genome, spanning altogether 25 SNPs. For the GWAS with **BALF5** as the outcome, the associated human genomic region contains eQTLs for the nearby gene *UNC5D*. This gene is poorly characterized but has been shown to play a role in the regulation of apoptosis [69]. The other two EBV genes (**BRLF1, BBRF1**) provided little indication of what underlying mechanism might be at play.

Our study is limited by its small sample size and by the complexity of correcting for human 13 14 and EBV population stratification. Indeed, if not carefully controlled for, the existence of 15 population structure in the host and pathogen genome might create spurious associations or 16 decrease real signals in G2G analyses, resulting in both type I and type II errors. With a mixed 17 model approach and the inclusion of pathogen principal components as covariates, the 18 genomic inflation factors of our GWAS ranged between 0.92 and 1.12. This wide range of 19 genomic inflation factors is likely due to a combination of small sample size and complex 20 statistical model. To prevent false positives, we adjusted for genomic inflation when extracting 21 significant SNPs and used a conservative G2G significance threshold of 5x10<sup>-8</sup> divided by the 22 effective number of GWAS performed. Although viral genetic variation is a more precise 23 phenotype to study than traditional outcomes, it comes at the price of decreased power due 24 to the high-dimensional outcome. The significance threshold is thus much lower than in a 25 single GWAS. To limit the number of statistical tests performed, we restricted our analysis to 26 common gene and amino acid variation.

27 Our analyses have been performed using historical samples collected from untreated HIV-28 infected individuals. Considering the natural history of EBV infection in humans and its high 29 likelihood to be acquired during the first 2 decades of life, we postulate that intra-host 30 adaptation of EBV happened before HIV infection, i.e. with a normally functioning immune 31 system. At the time of sample collection, all study participants had advanced 32 immunosuppression with low CD4+ T cell counts (< 200 cells/mm<sup>3</sup> of blood). We therefore 33 assume an absence of selective pressure on EBV at that time. These assumptions limit 34 obviously the generalizability of our findings to non-HIV-infected population. Similar studies 35 performed during primary EBV infection or in other specific population (e.g. bone-marrow 36 transplant recipients) would help better delineate the global impact of intra-host selection on 37 EBV sequence variation.

Our study provides a preliminary list of statistical associations between the EBV and the human genomes. The cataloguing of the sites of host-pathogen genomic conflict is potentially useful for further functional exploration, as has been demonstrated for HIV and HCV infections. Our results require replication and validation in different cohorts and settings. Importantly, larger sample sizes will be needed to increase power and provide more robust estimations.

# **Data availability** 1

2 The datasets generated during and/or analysed during the current study are available in the 3 following Zenodo repositories: G2G results are in https://doi.org/10.5281/zenodo.4289138, 4 pathogen data in https://doi.org/10.5281/zenodo.4011995.

# References 5

- 6 1. Chapman, S. J. & Hill, A. V. S. Human genetic susceptibility to infectious disease. Nat. 7 Rev. Genet. 13, 175-188 (2012).
- 8 2. Casanova, J.-L. & Abel, L. The human genetic determinism of life-threatening infectious 9 diseases: genetic heterogeneity and physiological homogeneity? Hum Genet 139, 681-694 10 (2020).
- 11 3. Visscher, P. M. et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. 12 The American Journal of Human Genetics 101, 5–22 (2017).
- 13 4. Timmann, C. et al. Genome-wide association study indicates two novel resistance loci for 14 severe malaria. Nature 489, 443–446 (2012).
- 15 5. McLaren, P. J. et al. Association Study of Common Genetic Variants and HIV-1
- 16 Acquisition in 6,300 Infected Cases and 7,200 Controls. PLoS Pathogens 9, e1003515 17 (2013).
- 18 6. McLaren, P. J. et al. Polymorphisms of large effect explain the majority of the host genetic 19 contribution to variation of HIV-1 virus load. PNAS 112, 14658–14663 (2015).
- 20 7. Rubicz, R. et al. A Genome-Wide Integrative Genomic Study Localizes Genetic Factors 21 Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1). PLoS
- 22 Genetics 9, e1003147 (2013).
- 23 8. Zhou, Y. et al. Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with 24 risk of multiple sclerosis. Mult. Scler. 22, 1655–1664 (2016).
- 25 9. Hammer, C. et al. Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of 26 Humoral Response to Common Viruses. The American Journal of Human Genetics 97, 738-27 743 (2015).
- 28 10. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral 29 clearance. Nature 461, 399-401 (2009).
- 30 11. Alizon, S., Luciani, F. & Regoes, R. R. Epidemiological and clinical consequences of 31 within-host evolution. Trends in Microbiology 19, 24-32 (2011).
- 32 12. Fraser, C. et al. Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary 33 Perspective. Science 343, 1243727 (2014).
- 34 13. Farci, P. et al. The Outcome of Acute Hepatitis C Predicted by the Evolution of the Viral 35 Quasispecies. Science 288, 339-344 (2000).
- 36 14. Didelot, X., Walker, A. S., Peto, T. E., Crook, D. W. & Wilson, D. J. Within-host evolution 37 of bacterial pathogens. Nature Reviews Microbiology 14, 150-162 (2016).

- 1 15. Bartha, I. et al. A genome-to-genome analysis of associations between human genetic 2 variation, HIV-1 sequence diversity, and viral control. Elife 2, e01123 (2013).
- 3 16. Cohen, J. I. Epstein-barr virus vaccines. Clin Transl Immunology 4, e32 (2015).
- 4 17. Ansari, M. A. et al. Genome-to-genome analysis highlights the effect of the human innate 5 and adaptive immune systems on the hepatitis C virus. Nature Genetics 49, 666–673 (2017).
- 6 18. Ansari, M. A. et al. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. 7 Elife 8, (2019).
- 8 19. Chaturvedi, N. et al. Adaptation of hepatitis C virus to interferon lambda polymorphism 9 across multiple viral genotypes. eLife 8, e42542 (2019).
- 10 20. Duffy, S., Shackelton, L. A. & Holmes, E. C. Rates of evolutionary change in viruses: 11 patterns and determinants. Nature Reviews Genetics 9, 267-276 (2008).
- 12 21. Cudini, J. et al. Human cytomegalovirus haplotype reconstruction reveals high diversity 13 due to superinfection and evidence of within-host recombination. Proc Natl Acad Sci USA 14 **116**, 5693 (2019).
- 15 22. Kwok, H. et al. Genomic Diversity of Epstein-Barr Virus Genomes Isolated from Primary 16 Nasopharyngeal Carcinoma Biopsy Samples. Journal of Virology 88, 10662–10672 (2014).
- 17 23. Palser, A. L. et al. Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types 18 and Normal Infection. Journal of Virology 89, 5222-5237 (2015).
- 19 24. Balfour, H. H. et al. Age-specific prevalence of Epstein-Barr virus infection among
- 20 individuals aged 6-19 years in the United States and factors affecting its acquisition. J. 21 Infect. Dis. 208, 1286–1293 (2013).
- 22 25. Green, M. & Michaels, M. G. Epstein-Barr Virus Infection and Posttransplant 23 Lymphoproliferative Disorder: EBV and PTLD. American Journal of Transplantation 13, 41-24 54 (2013).
- 25 26. Pender, M. P. The essential role of Epstein-Barr virus in the pathogenesis of multiple 26 sclerosis. Neuroscientist 17, 351-367 (2011).
- 27 27. Pender, M. P. & Burrows, S. R. Epstein-Barr virus and multiple sclerosis: potential 28 opportunities for immunotherapy. Clin Transl Immunology 3, e27 (2014).
- 29 28. Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 30 757–768 (2004).
- 31 29. Ko, Y.-H. EBV and human cancer. Experimental & Molecular Medicine 47, e130 (2015).
- 32 30. de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review 33 and synthetic analysis. The Lancet Oncology 13, 607-615 (2012).
- 34 31. Khan, G. & Hashim, M. J. Global burden of deaths from Epstein-Barr virus attributable 35 malignancies 1990-2010. Infectious Agents and Cancer 9, 38 (2014).
- 36 32. Hammerschmidt, W. & Sugden, B. Replication of Epstein-Barr viral DNA. Cold Spring 37 Harb Perspect Biol 5, a013029 (2013).

- 1 33. Xu, M. et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes
- 2 associated with high risk of nasopharyngeal carcinoma. Nature Genetics 1 (2019) 3 doi:10.1038/s41588-019-0436-5.
- 4 34. Wegner, F., Lassalle, F., Depledge, D. P., Balloux, F. & Breuer, J. Co-evolution of sites 5 under immune selection shapes Epstein-Barr Virus population structure. Mol Biol Evol 6 (2019) doi:10.1093/molbev/msz152.
- 7 35. Kaymaz, Y. et al. Epstein Barr virus genomes reveal population structure and type 1 8 association with endemic Burkitt lymphoma. bioRxiv 689216 (2019) doi:10.1101/689216.
- 9 36. Havward, T. A. et al. Antibody response to common human viruses is shaped by genetic 10 factors. Journal of Allergy and Clinical Immunology 143, 1640–1643 (2019).
- 11 37. The Swiss HIV Cohort Study et al. Cohort Profile: The Swiss HIV Cohort Study. 12 International Journal of Epidemiology 39, 1179–1189 (2010).
- 13 38. Depledge, D. P. et al. Specific Capture and Whole-Genome Sequencing of Viruses from 14 Clinical Samples. PLOS ONE 6, e27805 (2011).
- 15 39. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114-2120 (2014). 16
- 17 40. Lassmann, T. TagDust2: a generic method to extract reads from sequencing data. BMC 18 Bioinformatics 16, 24 (2015).
- 19 41. Fu, L., Niu, B., Zhu, Z., Wu, S. & Li, W. CD-HIT: accelerated for clustering the next-20 generation sequencing data. *Bioinformatics* 28, 3150–3152 (2012).
- 21 42. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-22 generation DNA sequencing data. Nat Genet 43, 491-498 (2011).
- 23 43. Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls; the
- 24 Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics 43, 11.10.1-25 11.10.33 (2013).
- 26 44. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 27 arXiv:1303.3997 [q-bio] (2013).
- 28 45. McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing 29 next-generation DNA sequencing data. Genome Res 20, 1297-1303 (2010).
- 30 46. Correia, S. et al. Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary 31 MicroRNA. J Virol 91, (2017).
- 32 47. Wei, Z., Wang, W., Hu, P., Lyon, G. J. & Hakonarson, H. SNVer: a statistical tool for 33 variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic 34 Acids Res. 39, e132 (2011).
- 35 48. Koboldt, D. C. et al. VarScan: variant detection in massively parallel sequencing of 36 individual and pooled samples. *Bioinformatics* 25, 2283–2285 (2009).
- 37 49. Cingolani, P. et al. A program for annotating and predicting the effects of single
- 38 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain
- 39 w1118; iso-2; iso-3. Fly (Austin) 6, 80-92 (2012).

- 1 50. Köster, J. & Rahmann, S. Snakemake—a scalable bioinformatics workflow engine.
- Bioinformatics 28, 2520–2522 (2012). 2
- 3 51. Python Language Reference. (Python Software Foundation).
- 4 52. Josse, J. & Husson, F. missMDA: A Package for Handling Missing Values in Multivariate 5 Data Analysis. Journal of Statistical Software 70, 1–31 (2016).
- 6 53. Loh, P.-R. et al. Reference-based phasing using the Haplotype Reference Consortium 7 panel. Nature Genetics 48, 1443-1448 (2016).
- 8 54. Durbin, R. Efficient haplotype matching and storage using the positional Burrows-9 Wheeler transform (PBWT). Bioinformatics 30, 1266-1272 (2014).
- 10 55. The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68-74 (2015). 11
- 12 56. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer 13 datasets. GigaScience 4, 7 (2015).
- 14 57. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide 15 Complex Trait Analysis. The American Journal of Human Genetics 88, 76-82 (2011).
- 16 58. Yang, J., Zaitlen, N. A., Goddard, M. E., Visscher, P. M. & Price, A. L. Advantages and 17 pitfalls in the application of mixed-model association methods. Nature Genetics 46, 100–106 18 (2014).
- 19 59. Naret, O. et al. Correcting for Population Stratification Reduces False Positive and False 20 Negative Results in Joint Analyses of Host and Pathogen Genomes. Front. Genet. 9, (2018).
- 21 60. Landgraf, A. J. & Lee, Y. Dimensionality Reduction for Binary Data through the
- 22 Projection of Natural Parameters. arXiv:1510.06112 [stat] (2015).
- 23 61. R Development Core Team. R: A Language and Environment for Statistical Computing. 24 (R Foundation for Statistical Computing, 2008).
- 25 62. Gao, X., Starmer, J. & Martin, E. R. A multiple testing correction method for genetic 26 association studies using correlated single nucleotide polymorphisms. Genet. Epidemiol. 32,
- 27 361-369 (2008).
- 28 63. Benner, C. et al. FINEMAP: efficient variable selection using summary data from 29 genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- 30 64. Benner, C. et al. Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using
- 31 Summary Statistics from Genome-wide Association Studies. The American Journal of 32 Human Genetics 101, 539-551 (2017).
- 33 65. Võsa, U. et al. Unraveling the polygenic architecture of complex traits using blood eQTL 34 meta-analysis. http://biorxiv.org/lookup/doi/10.1101/447367 (2018) doi:10.1101/447367.
- 35 66. Ferreira, M. A. R. et al. Gene-based analysis of regulatory variants identifies 4 putative
- 36 novel asthma risk genes related to nucleotide synthesis and signaling. J. Allergy Clin. 37 Immunol. 139, 1148–1157 (2017).
- 38 67. Carithers, L. J. et al. A Novel Approach to High-Quality Postmortem Tissue Procurement: 39 The GTEx Project. *Biopreserv Biobank* 13, 311–319 (2015).

- 1 68. Sandmann, S. et al. Evaluating Variant Calling Tools for Non-Matched Next-Generation
- 2 Sequencing Data. Scientific Reports 7, 43169 (2017).
- 69. Wang, H. et al. Unc5D regulates p53-dependent apoptosis in neuroblastoma cells. Mol 3 4 Med Rep 9, 2411–2416 (2014).
- 70. Jia, Y. et al. Sequence analysis of the Epstein-Barr virus (EBV) BRLF1 gene in 5
- 6 nasopharyngeal and gastric carcinomas. Virol J 7, 341 (2010).

# Consortium 7

### 8 Members of the Swiss HIV Cohort Study:

9 Karoline Aebi-Popp<sup>9</sup>, Alexia Anagnostopoulos<sup>10</sup>, Manuel Battegay<sup>11</sup>, Enos Bernasconi<sup>12</sup>, Jürg Böni<sup>13</sup>, Dominique Braun<sup>10</sup>, Heiner Bucher<sup>14</sup>, Alexandra Calmy<sup>15</sup>, Matthias Cavassini<sup>16</sup>, Angela 10 Ciuffi<sup>17</sup>, Guenter Dollenmaier<sup>18</sup>, Matthias Egger<sup>19</sup>, Luigia Elzi<sup>11</sup>, Jan Fehr<sup>10</sup>, Jacques Fellay<sup>1</sup>, 11 12 Hansjakob Furrer<sup>9</sup>, Christoph Fux<sup>20</sup>, Huldrych Günthard<sup>10</sup>, David Haerry<sup>21</sup>, Barbara Hasse<sup>10</sup>, Hans Hirsch<sup>22,23</sup>, Matthias Hoffmann<sup>24</sup>, Irene Hösli<sup>25</sup>, Michael Huber<sup>13</sup>, Christian Kahlert<sup>24,26</sup>, 13 Laurent Kaiser<sup>27</sup>, Olivia Keiser<sup>28</sup>, Thomas Klimkait<sup>22</sup>, Lisa Kottanattu<sup>29</sup>, Roger Kouyos<sup>10</sup>, Helen 14 Kovari<sup>10</sup>, Bruno Ledergerber<sup>10</sup>, Gladys Martinetti<sup>30</sup>, Begoña Martinez de Tejada<sup>31</sup>, Catia 15 Marzolini<sup>11</sup>, Karin Metzner<sup>10</sup>, Nicolas Müller<sup>10</sup>, Dunja Nicca<sup>24</sup>, Paolo Paioni<sup>32</sup>, Giuseppe 16 Pantaleo<sup>33</sup>, Matthieu Perreau<sup>33</sup>, Andri Rauch<sup>9</sup>, Christoph Rudin<sup>34</sup>, Alexandra Scherrer<sup>10,35</sup>, 17 18 Patrick Schmid<sup>24</sup>, Roberto Speck<sup>10</sup>, Marcel Stöckle11, Philip Tarr<sup>36</sup>, Alexandra Trkola<sup>13</sup>, Pietro

- Vernazza<sup>24</sup>, Noémie Wagner<sup>37</sup>, Gilles Wandeler<sup>9</sup>, Rainer Weber<sup>10</sup>, Sabine Yerly<sup>38</sup> 19
- 20
- 21 <sup>9</sup> Department of Infectious Diseases, Bern University Hospital, University of Bern,
- 22 Switzerland
- <sup>10</sup> Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 23
- 24 University of Zurich, Switzerland
- 25 <sup>11</sup> Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel,
- University of Basel, Switzerland 26
- <sup>12</sup> Division of Infectious Diseases, Regional Hospital Lugano, Switzerland 27
- <sup>13</sup> Institute of Medical Virology, University of Zürich, Switzerland 28
- 29 <sup>14</sup> Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel,
- 30 University of Basel, Switzerland
- 31 <sup>15</sup> Division of Infectious Diseases, University Hospital Geneva, University of Geneva,
- 32 Switzerland
- 33 <sup>16</sup> Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne,
- 34 Switzerland
- <sup>17</sup> Institute of Microbiology, University Hospital Lausanne, University of Lausanne, 35
- 36 Switzerland
- 37 <sup>18</sup> Centre for Laboratory Medicine, Canton St.Gallen, Switzerland
- <sup>19</sup> Institute of Social and Preventive Medicine, University of Bern, Switzerland 38
- 39 <sup>20</sup> Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland
- <sup>21</sup> Deputy of the patient organization "Positive Council", Switzerland 40
- 41 <sup>22</sup> Division Infection Diagnostics, Department Biomedicine - Petersplatz, University of Basel,
- 42 Switzerland

- <sup>23</sup> Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, 1
- 2 Switzerland
- <sup>24</sup> Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St.Gallen, 3
- 4 Switzerland
- <sup>25</sup> Clinic for Obstetrics, University Hospital Basel, University of Basel, Switzerland 5
- 6 <sup>26</sup> Childrens Hospital of Eastern Switzerland, St.Gallen, Switzerland
- 7 <sup>27</sup> Division of Infectious Diseases and Laboratory of Virology, University Hospital Geneva,
- 8 University of Geneva, Switzerland
- 9 <sup>28</sup> Institute of Global Health, University of Geneva, Switzerland
- 10 <sup>29</sup> Pediatria, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland
- 11 <sup>30</sup> Cantonal Institute of Microbiology, Bellinzona, Switzerland
- <sup>31</sup> Department of Obstetrics and Gynecology, University Hospital Geneva, University of 12
- 13 Geneva, Switzerland
- <sup>32</sup> University Children's Hospital, University of Zurich, Switzerland 14
- 15 <sup>33</sup> Division of Immunology and Allergy, University Hospital Lausanne, University of
- 16 Lausanne, Switzerland
- <sup>34</sup> University Childrens Hospital, University of Basel, Switzerland 17
- <sup>35</sup> Swiss HIV Cohort Study, Data Centre 18
- <sup>36</sup> Kantonsspital Baselland, University of Basel, Switzerland 19
- 20 <sup>37</sup> Pediatria, University Hospital Geneva, University of Geneva, Switzerland
- <sup>38</sup> Laboratory of Virology, University Hospital Geneva, University of Geneva, Switzerland 21

# **Acknowledgments** 22

- 23 This study was supported by the Leenaards Foundation (Leenaards Prize 2015 to JF and
- 24 EZ). This study has also been partly financed within the framework of the Swiss HIV Cohort
- 25 Study, supported by the Swiss National Science Foundation (grant #177499), by SHCS
- 26 project #743 and by the SHCS research foundation. The data are gathered by the Five
- 27 Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private
- 28 physicians (listed in http://www.shcs.ch/180-health-care-providers).

# **Author contributions** 29

- 30 EZ and JF conceived and supervised the work.
- 31 SR and CH performed the association analyses.
- 32 DPD, SM, JB performed EBV sequencing and curated the data.
- 33 AL prepared and analysed the viral sequencing data.
- 34 PJM, DL, ON contributed to the design of the work.
- 35 SHCS collected the samples and associated data.
- 36 SR, CH, AL and JF wrote the paper.
- 37 All authors reviewed the manuscript and approved the submission.
- 38
- 39
- 40

# **Additional information** 1

- **Competing interests** 2
- 3 CH is an employee of Genentech.

# **Figure legends** 4

- 5 Figure 1: Illustration of EBV sequence variation.
- 6 A) The EBV genome is about 170 Kbp long and contains 83 genes, for a total of 4392 amino
- 7 acid residues. As an example, we focus on the *BNRF1* gene and on two amino acid changes:
- Glu→Ala and Ser→Leu. We know for each sample the genomic variants across the whole 8
- 9 genome, as illustrated with the colored nucleotides. Using the nucleotide information and a
- 10 reference genome we can compute the amino acid changes.
- 11 B) We compare each individual (ID) to reference data and encode an amino acid as 1 if that
- 12 individual has a non-synonymous change, and a 0 if not. This process returns us a matrix
- 13 containing binary values, with individuals as row, and amino acids as columns. In our example,
- 14 individual 2 has an amino acid change Glu-Ala and individual 3 an amino acid change
- 15 Ser→Leu.
- 16 C) To transform the data into outcomes for the G2G analysis we can use the amino acid matrix
- 17 as it is (EBV amino acids dataset) or remove all amino acid columns that appear in more than
- 18 1 individual and then pool amino acids per gene (1 = variant present, *EBV genes* dataset).
- 19
- 20 Figure 2: Significant associations - A: BALF5, B: BBRF1, C: BRLF1:p.Lys316Glu.
- 21 The x-axis represents the chromosomal position and the y-axis displays the -log10(p-value).
- 22 Colour alternates between chromosomes. Regions that contain statistically significant SNP
- 23 are presented in red (top SNP +/- 400 Kbp). The light grey dashed line represents the GWAS
- 24 significance threshold of  $5 \times 10^{-8}$ , the dark grey dashed line the G2G threshold of  $1.09 \times 10^{-10}$ .
- 25
- 26 Figure 3: Locuszoom plots.

27 Locuszoom plots for the three EBV association signals highlighted in red in Figure 2 (A: 28 BALF5, B: BBRF1, C: BRLF1:p.Lys316Glu).

- 29
- 30
- 31
- 32
- 33
- 34
- 35

medRxiv preprint doi: https://doi.org/10.1101/2020.12.02.20242370; this version posted December 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

1	
2	
3	
4	
5	

6

# 7 Tables

dataset	variable	counts	mean	median	sd	min	max
Pathogen genome (83 Rare							
EBV gene variation)	Variant frequency		0.067	0.049	0.057	0	0.37
Pathogen genome (575							
EBV amino acids)	Variant frequency		0.26	0.24	0.12	0.093	0.5
		male: 206,					
Covariates	Sex	female: 62					
Covariates	AGE		42.02	40.79	10.98	20.25	77.52
						-	
Covariates	PC1		-8.95	-7.12	32.53	69.95	76.11
						-	
Covariates	PC2		7.39	8.4	30.41	63.83	61.8
						-	
Covariates	PC3		4.45	3.19	21.41	46.44	51.11
						-	
Covariates	PC4		-3.91	-6.69	20.72	36.49	52.11
Covariates	PC5		-5.09	-8.39	18.76	-51.7	56.02
						-	
Covariates	PC6		-3.16	-3.21	18.65	55.69	35.68
Covariates	EBV type		0.54	0.95	0.67	-1	1

8

9 Table 1: Summary of pathogen variants, host SNPs and covariates for 268 individuals. For 10 each covariate, we indicate the number of individuals measured, and distribution (mean, 11 median, standard deviation, minimum, maximum for quantitative, frequency for sex). For 12 aggregated EBV genes the frequency is shown, for host SNPs the MAF distribution is

13 presented.

	EBV						Finemapped	Finemapped	Effect				
Locus	dataset	EBV outcome	SNP	Chr	OR**	р	SNP	probability	allele	EAF	n	gene	Consequence type
	gene												
	(binary,												
	variants												
	< 1												
2	sample)	BALF5	rs2950922*	8	1.30739	4.2E-12	TRUE	0.13317	G	0.10821	268	UNC5D***	intron_variant
	gene												
	(binary,												
	variants												
	< 1												
3	sample)	BBRF1	rs62124869*	2	1.29103	4.3E-11	TRUE	0.71847	С	0.0541	268	LINC01830	non_coding_transcript_variant
	amino												
	acid												
1	(binary)	BRLF1:p.Lys316Glu	rs7808072*	7	1.41346	6.8E-11	FALSE		Т	0.06762	244		
	amino												
	acid												
1	(binary)	BRLF1:p.Lys316Glu	rs6466720	7	1.42464	7.7E-11	TRUE	0.04783	G	0.06967	244		
	1												

2 \* SNP with locus-wide lowest P-value

3 \*\* Odds ratio (exp(b) for logistic mixed effects model) in SHCS

4 \*\*\* Gene and tissue of eqtl association (P-value of association), from GTEX:

5 UNC5D in Esophagus\_Muscularis (P=1.15243e-13), UNC5D in Esophagus\_Gastroesophageal\_Junction (P=2.61983e-05)

6

7 Table 2: Summary of G2G analysis results. Top SNP and/or fine-mapped SNP per locus represented with: EBV dataset, EBV outcome,

8 chromosome, SNP identifier, odds ratio, p-value, whether this SNP is a top SNP or a fine-mapped SNP, the causal probability from FINEMAP,

9 effect allele, effect allele frequency, sample size, corresponding gene, variant consequence, associated eQTL gene, associated eQTL associated

10 eQTL gene and p-value in GTEx (from https://gtexportal.org/home/) [67]. See Supplementary Table S1 for detailed information about all 25

11 variants and Supplementary Table S2 for fine-mapping results.

### A. EBV genes and amino acids tooph



### B. Data water con yes

	D	SNV 1	ON 2	SNVS	SNY 4	SHYE	ONV 0			
1	1	G	A	G	Т		G			
	2	G	C	G	T T	т	G			
	3	G	A	G		C				
	4	G	A	G	т		G			
			-		_	-				
	D		Amino ecki 1 Gik y Ala D			Amino acid 7 Onr > Leu				
	1					0				
	2		1		0					
	3		0			1				
			0			0				


### C. Datasets


### # 575 EBV amino acids


1 = scraxt present 2 = no nariant present.

### 52 EBV genes

Dry appropriate write acts that appear is one individual. 1 a at ward one variant passent 0 - na variant present.








С






### BBRF1

В


С

Α

Plotted SNPs



BRLF1:p.Lys316Glu



Position on chr7 (Mb)